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Abstract. Proton pump inhibitors (PPIs) are frequently 
prescribed to patients with gastroesophageal reflux disease; 
however, the number of bone fractures reportedly increased in 
these patients. Although PPIs have been shown to inhibit the 
bone resorption by osteoclasts, the effect of PPIs on skeletal 
metabolism remains controversial. The aim of the present 
study was to determine the effect of the PPI rabeprazole on 
skeletal metabolism using gastrectomized rats. Male Wistar 
rats were divided into four groups: i) Sham‑surgery (n=15); 
ii) total gastrectomy (TG) control (n=20); iii) TG plus rabepra‑
zole (n=20); and iv) TG plus the bisphosphonate minodronic 
acid (n=20). Twenty‑two weeks after TG, the rats were sacri‑
ficed, and bone mineral density (BMD), bone strength and 
markers for bone metabolism were measured. Compared with 
the control group (50.0±8.1%), the TG‑induced decrease in 
BMD was significantly ameliorated in the rabeprazole group 
(56.5±7.5%) and the minodronic acid group (59.0±6.0%). 
However, rabeprazole did not improve bone strength. 
In conclusion, rabeprazole does not appear to exacerbate bone 
metabolic disorders in gastrectomized rats, but rather amelio‑
rates the TG‑induced BMD decrease.
Introduction
Osteoporosis is a well‑known disease and caused 9 million 
osteoporotic fractures worldwide in the year 2000 (1). 
Osteoporotic fractures occurring at the spine and the 
forearm are associated with significant morbidity, but the 
most serious consequences arise in patients with hip frac‑
tures. The mortality rate is 20% in the first year following 
hip fracture (2). Among those who survive this period, 1 in 5 
requires nursing home care (3). Thus, osteoporosis is associ‑
ated with not only morbidity, but also decline in the quality 
of life. Osteoporosis is classified as primary osteoporosis 
induced by menopause or aging and secondary osteoporosis. 
Well‑known causes of secondary osteoporosis include, 
endocrine disorders, such as Cushing's syndrome, hypogo‑
nadism, hyperthyroidism, hyperparathyroidism and diabetes 
mellitus (4). Gastrointestinal diseases, such as inflammatory 
bowel disease (5), rheumatoid arthritis (6) and myeloma 
bone disease (7), also induce osteoporosis. In addition, the 
incidence of osteoporosis following gastrectomy has become 
a clinical issue. Although numerous studies have examined 
bone metabolic disorders following gastrectomy since it was 
first reported by Sarasin (8), the pathophysiology and the 
treatment of these disorders have not been fully elucidated. 
Based on experimental results using rat models, general nutri‑
tional deficiencies (9), calcium malabsorption (10), vitamin D 
deficiency (11), loss of gastric acid (12) and secondary hyper‑
parathyroidism (13) have been suggested as possible causes 
of bone metabolic disorder following gastrectomy. However, 
fully understanding the morbidity and developing clinical 
therapies for skeletal disorders is critical for improving 
patient quality of life.
Recent epidemiological studies have shown that long‑term 
therapy with proton pump inhibitors (PPIs) significantly 
increases the risk of osteoporosis and pathological hip frac‑
ture in patients with gastroesophageal reflux disease (14). It 
is thought that PPIs reduce the production and secretion of 
hydrochloric acid in stomach, increase the pH in the stomach 
and inhibit absorption of insoluble calcium in the small 
intestine, thus leading to malabsorption of calcium phosphate 
and bone metabolism disorder (15,16). PPIs also reportedly 
inhibit bone resorption by osteoclasts (17,18). However, the 
irreversible PPI mediated by the PPIs requires a specific pH 
environment. PPIs are all prodrugs that require two sequential 
protonation steps for activation (19). In the first step, a pyridine 
radical is activated, and in the second step, a benzimidazole 
radical is activated. The first step is required for accumulation 
of the PPI in the intracellular secretory canaliculus, and the 
second step is necessary for binding of the PPI with the proton 
pump. The pKa in the second step does not significantly differ 
(<1) among the various PPIs (such as rabeprazole, lansopra‑
zole and omeprazole), whereas the pKa for the first step with 
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rabeprazole (4.53) is higher compared to that for lansoprazole 
(3.83) and omeprazole (4.06) (20). This suggests that rabepra‑
zole can efficiently combine with the proton pump to produce 
an immediate effect (21). For the two sequential protonation 
steps, the proton pump inhibitory action of the PPIs is 
extremely site‑specific. In addition to the secretory canaliculi 
of the gastric parietal cells, the osteoclastic resorption vacuole 
may be the only other place in which proton pump inhibition 
by PPIs is known to occur. Clinical studies have supported the 
theory that the short‑term use of a PPI reduces bone resorption 
markers (18,22). There are conflicting data regarding the effect 
of PPIs on bone metabolism, with little known concerning the 
effects of PPIs on osteoclasts and bone resorption.
Therefore, the present study analyzed the effect of PPIs 
on bone metabolism following total gastrectomy (TG) in a rat 
model of osteoporosis. Using the rat TG model, poor calcium 
absorption that is observed during gastric anacidity was 
reproduced and the confounding antisecretory activity of the 
PPI was excluded to determine the specific effect of a PPI on 
osteoclasts.
Materials and methods
Ethical approval. All the procedures performed in the studies 
involving animals adhered to the Standard Guidelines for 
Animal Experiments at Kanazawa University (Kanazawa, 
Ishikawa, Japan; date of issue: May 18, 2012; registration 
number: AP‑122484).
Animals. In total, 75 male Wistar rats (Charles River 
Laboratories Japan, Inc., Kanagawa, Japan) that were 12 weeks 
of age were used for the experiments. The rats were housed 
three to a cage, and were maintained at a room temperature 
of 22±3˚C and humidity of 55±5% with a 12‑h light‑dark 
cycle. The rats were provided a standard solid chow, CRF‑1 
(Charles River Laboratories Japan, Inc.) and tap water. The 
animal welfare committee of Kanazawa University approved 
the experiments.
Drugs. The effects of the PPI rabeprazole on bone metabolism 
were compared with those of minodronic acid, a bisphospho‑
nate clinically administered in the treatment of patients with 
osteoporosis. Minodronic acid was obtained from Astellas 
Pharma, Inc. (Tokyo, Japan), and rabeprazple was obtained 
from Eisai Co., Ltd. (Tokyo, Japan).
Experimental design. The rats were randomly divided into the 
following four groups: i) Sham‑surgery (n=15); ii) TG control 
(n=20); iii) TG plus rabeprazole (30 mg/kg) administered 
three times per week (n=20); iv) TG plus minodronic acid 
(0.04 mg/kg/day) (n=20). Beginning 4 weeks after surgery, 
rabeprazole was administered subcutaneously three times per 
week for 18 weeks to the rats in the TG plus rabeprazole group, 
and minodronic acid was administered subcutaneously daily 
for 18 weeks to the rats in the TG plus minodronic acid group. 
The rationale for the dose of rabeprazole used was based on 
prior studies, which showed that a subcutaneous dose of rabe‑
prazole at 30 mg/kg to rats reduced acid secretion by 100% 
within 4 h, with the return of acid secretion to normal levels 
at 3 days (23,24).
Surgery. After 24 h of fasting, the rats were anesthetized 
with intraperitoneal injections of medetomidine, midazolam 
and butorphanol. TG using the reconstructed Roux‑en‑Y 
method was performed through an upper middle incision. The 
duodenal stump was closed with sutures. The jejunum was 
amputated ~6 cm distal to the ligament of Treitz. The esopha‑
geal stump was anastomosed to the anal side of amputated 
jejunum in an end‑to‑side manner. The jejunojejunostomy was 
performed in a side‑to‑side manner. Intestinal anastomosis 
was performed with interrupted full‑thickness stitches using 
7‑0 monofilament suture. The rats had free access to water and 
food beginning 24 h after surgery.
Autopsy. Blood samples were obtained and the animals were 
sacrificed by exsanguination under isoflurane anesthesia 
22 weeks after the surgery. The serum samples were immedi‑
ately separated from the blood by centrifugation at 1,000 x g 
for 10 min, and the serum was frozen and stored at ‑80˚C 
until used for analysis. Femurs were isolated for evaluation, 
and the soft tissue was removed. Femurs were wrapped in 
saline‑soaked gauze and stored at ‑80˚C until used for analysis.
Bone morphometry and density. The right femur was fixed in 
10% neutral buffered formalin, degreased in 100% ethanol, 
re‑fixed in cyanuric chloride (Wako Pure Chemical Industries, 
Osaka, Japan) and decalcified with formic acid. Thin sections 
of the right femur were made with a sliding microtome (Leica 
SM‑2000R; Leica Biosystems, Nussloch, Germany). The 
sections were stained with hematoxylin and eosin (H&E) 
stain. The amount and width of each trabecular bone, corre‑
lated with bone strength, was traced distal to epiphyseal line 
using a bio‑imaging navigator (Biorevo BZ‑9000; Keyence, 
Osaka, Japan). The range of calcified bone was extracted. The 
area of the calcified bone in the traced range was calculated 
using analytical software (Hybrid Cell Count Software; 
Keyence).
Bone strength. The bending strength of the left femur was 
measured with a three‑point bending test using a mechanical 
testing machine (AG‑X; Shimadzu, Kyoto, Japan). The 
specimen was placed horizontally in the loading section of 
the machine. The center of the diaphysis was pressed with 
50 kgf; the distance from the support point was 15 mm. The 
breaking strength in Newtons (N) was used as a measure of 
bone strength.
Serum biochemistry. Biochemical measurements, including 
serum calcium, phosphorus, total protein and albumin were 
measured with an auto‑analyzer (Hitachi 7180; Hitachi 
High‑Technologies, Tokyo, Japan).
Bone metabolism. Serum tartrate‑resistant acid phosphatase 5b 
(TRACP‑5b), a bone resorption marker, and bone‑specific 
alkaline phosphatase (BAP), a bone formation marker, were 
used as biochemical markers of turnover and, measured using 
an enzyme immunoassay (Rat TRACP‑5b ELISA; Cusabio 
Biotech Co., Ltd., Wuhan, China).
Statistical analysis. Continuous variables are expressed as 
mean ± standard deviation. Comparisons between groups were 
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made using the Mann‑Whitney U test. P<0.05 was considered 
to indicate a statistically significant difference.
Results
Final sample numbers. Subsequent to being assigned to the 
experimental groups, 1 rat died in the TG plus rabeprazole 
group, and 3 rats died in the TG plus minodronic acid group. 
All 4 rats succumbed to ileus; none from drug toxicity. No 
rats died in the sham‑surgery or TG control groups. Of the 
75 assigned animals, 71 rats survived 22 weeks post‑surgery 
and were included in the study (15 in the sham group, 20 in the 
TG control group, 19 in the TG plus rabeprazole group, and 17 
in the TG plus minodronic acid group).
Body weights. Changes in the body weights of the rats in each 
experimental group are shown in Fig. 1. Body weights of the 
rats in the TG group were reduced in weeks 1‑2. The body 
weights of the rats in the sham group increased gradually 
throughout the study period, whereas those in the TG groups 
remained nearly constant after week 8. No significant differ‑
ences in the body weights were observed among the three TG 
groups.
Bone mineral density (BMD) of the femur. Twenty‑two weeks 
after TG, the rate of the calcified bone area in the traced are 
in the TG control group (50.0±8.1%) was lower than that in 
the sham group (69.0±5.6%) (Fig. 2). The rates in the TG 
plus rabeprazole (56.5±7.5%) and TG plus minodronic acid 
(59.0±6.0%) groups were significantly higher than that in 
the TG control group (P<0.05). These results indicated that 
rabeprazole inhibited the TG‑induced BMD decrease with an 
effect comparable to that of minodronic acid (Fig. 2).
Bone strength. Femoral bending strength was markedly 
decreased in the TG control group (152.34±24.01 N•m) 
compared with that in the sham group (251.99±23.14 N•m). 
This effect was significantly ameliorated and also counteracted 
with minodronic acid treatment (190.50±26.95 N•m), but not 
by the rabeprazole treatment (151.67±22.41 N•m) (Fig. 3).
Serum biochemistry. Compared with that in the sham group, 
the serum calcium levels were reduced in rats with TG, while 
the serum phosphorus levels remained unchanged by TG 
or by the administration of either minodronic acid or rabe‑
prazole. Minodronic acid significantly decreased the serum 
calcium level compared with the level in the TG control 
Figure 1. Changes in body weight of the rats 22 weeks after surgery in each experimental group. The body weights of the rats in the sham group increased 
gradually throughout the study period, whereas those in the TG groups remained nearly constant after week 8. No significant differences were observed in 
body weights between the three TG groups. TG, total gastrectomy.
Figure 2. Bone mineral density of the femoral bone. Twenty‑two weeks after surgery, the rate of the calcified bone area in the traced area in the TG control 
group (50.0±8.1%) was lower than that in the sham group (69.0±5.6%). The rates in the TG plus rabeprazole (56.5±7.5%) and TG plus minodronic acid 
(59.0±6.0%) groups were significantly higher than that in the TG control group (*P<0.05). TG, total gastrectomy.
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group (P<0.05). By contrast, rabeprazole did not affect serum 
calcium levels (Fig. 4).
Bone metabolism. No significant differences in serum 
TRACP‑5b levels were observed between the four groups 
(Fig. 5A). The serum BAP level was reduced in rats with TG 
compared with that in the sham group. The administration of 
minodronic acid or rabeprazole did not ameliorate this serum 
BAP decrease (Fig. 5B).
Bone morphology. The morphology of the femoral metaphysis 
stained with H&E stain was observed microscopically (Fig. 6). 
The trabecular sponge‑like network in the metaphysis (arrow‑
head in Fig. 6) and trabecular separation (asterisks in Fig. 6) 
were compared across the four groups. The width (bidirectional 
arrow in Fig. 6) in the TG control group was thinner than that 
in the sham group. By contrast, the width was wider in the 
rabeprazole and minodronic acid‑treated groups compared to 
the TG control group.
Discussion
The present study demonstrated the effects of rabeprazole on 
bone metabolic disorders in gastrectomized rats. Minodronic 
acid almost completely blocked the TG‑induced decreases in 
bone density and bone strength. Rabeprazole also inhibited the 
TG‑induced decrease in bone density.
PPIs reduce gastric acid secretion, and are thus widely 
used in conditions such as gastroesophageal ref lux, 
Zollinger‑Ellison syndrome, dyspepsia and peptic ulcer 
disease (25). For years, PPIs were considered safe, without 
any major complications during long‑term use (26). However, 
Yang et al (27) conducted a nested case‑control study using 
the General Practice Research Database and examined 
Figure 3. Femoral bending strength in the different groups. Femoral bending strength was markedly decreased in the TG control group (152.34±24.01 N•m) 
compared with that in the sham group (251.99±23.14 N•m; *P<0.05). Femoral bending strength in the TG plus minodronic acid group (190.50±26.95 N•m) was 
higher than that in the TG control group (*P<0.05). Whereas, femoral bending strength in the TG plus rabeprazole group (151.67±22.41 N•m) is equal with that 
in the TG control group. TG, total gastrectomy.
Figure 4. (A) Serum calcium and (B) phosphorus levels in the different groups. Compared with that in the sham group, the serum calcium levels were reduced 
in rats with TG (*P<0.05). Minodronic acid significantly decreased the serum calcium level compared with the level in the TG control group (*P<0.05). By con‑
trast, rabeprazole did not affect serum calcium levels. The serum phosphorus levels remained unchanged by TG or by the administration of either minodronic 
acid or rabeprazole. TG, total gastrectomy.
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the risk of hip fractures associated with PPI use. The study 
reported that the risk of hip fracture was markedly increased 
among long‑term users of high‑dose PPI therapy. PPIs were 
recently identified as an independent risk factor for osteopo‑
rotic fracture (14,27‑31). PPIs reportedly increase the risk of 
osteoporotic fracture by causing hypochlorhydria, reducing 
intestinal calcium absorption and subsequently inducing a 
negative calcium balance (26,30). However, existing studies 
provide conflicting information regarding the direct effects of 
PPIs on calcium absorption. Hansen et al (32) administered 
omeprazole (40 mg/day) to menopausal women for 30 days 
and reported that 30 days of continuous PPI therapy did not 
alter calcium absorption, suggesting that PPI‑associated hypo‑
chlorhydria does not reduce calcium absorption.
However, several in vitro studies have reported that PPIs 
inhibit the vacuolar‑ATPase of osteoclasts and reduce their 
activity (33,34). Sheraly et al (35) examined the potential of 
PPIs to prevent osteoclast‑mediated resorption of calcium 
phosphate cements in vivo. The study reported that the 
PPIs (pantoprazole and high‑dose omeprazole) produced a 
delay in osteoclast resorption. Ohta et al (22) administered 
rabeprazole (10 mg/day for 8 weeks) to 22 non‑osteoporotic 
patients presenting with upper gastrointestinal symptoms and 
investigated the effect of rabeprazole on bone metabolism. 
Figure 5. (A) Serum TRACP‑5b and (B) BAP levels in the different groups. No significant differences were observed in the serum TRACP‑5b levels between 
the four groups. The serum BAP level was reduced in rats with TG compared with that in the sham group (*P<0.05). The administration of minodronic acid 
or rabeprazole did not ameliorate this serum BAP decrease. TRACP‑5b, tartrate‑resistant acid phosphatase 5b; BAP, bone‑specific alkaline phosphatase; TG, 
total gastrectomy.
Figure 6. Micrographs of the femur, focusing on the metaphysis of the distal end (H&E stain). The morphology of the femoral metaphysis stained with H&E 
stain was observed microscopically. The trabecular sponge‑like network in the metaphysis (arrowhead) and trabecular separation (asterisks) were compared 
across the four groups. The width (bidirectional arrow) in the TG control group was thinner than that in the sham group. By contrast, the width was wider in 
both the rabeprazole and minodronic acid treated groups than in the TG control group. TG, total gastrectomy; H&E, hematoxylin and eosin.
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They reported that rabeprazole did not affect BAP, but signifi‑
cantly decreased type I collagen cross‑linked N‑telopeptides. 
However, in humans and rat models, the effect of PPIs on 
bone metabolism appears complicated as PPIs have contradic‑
tory effects: Inhibition of calcium absorption by gastric acid 
suppression versus inhibition of osteoclasts. The association 
between PPI‑associated hypochlorhydria and the decrease in 
calcium absorption remains controversial.
In the present study, the TG rat model was used to exclude 
the PPI‑induced effect on gastric acid secretion and examine 
the PPI‑induced inhibition of bone resorption mediated by 
osteoclasts in skeletal metabolism. The results demonstrated 
that rabeprazole ameliorated the reduction in bone density 
induced by TG at the distal end of the femur, indicating that 
rabeprazole may control osteoclastic bone resorption, similar 
to bisphosphonate.
However, rabeprazole did not ameliorate the reduction 
in bone strength at the femoral diaphysis. This may be due 
to the improvement in bone density by rabeprazole, which 
was milder than that of the bisphosphonate. The difference 
between cancellous bone and cortical bone may also be one of 
the causes. Iwamoto et al (36) examined the influence of TG 
on cortical and cancellous bones in rats. The study measured 
the bone mineral content and density and the mechanical 
strength of the femoral distal metaphysis and diaphysis. The 
TG‑induced osteopenia and deterioration in bone strength 
were more severe at skeletal sites rich in cancellous bone 
(distal metaphysis) compared with those rich in cortical bone 
(diaphysis). The present study measured bone density at the 
femoral distal metaphysis, rich in cancellous bone. However, 
bone strength was measured at the femoral diaphysis, rich 
in cortical bone and thus less affected by gastrectomy or 
medication than cancellous bone. This may be one reason that 
administration of rabeprazole did not appear to affect bone 
strength in the present study.
The serum BAP level in the TG groups was significantly 
lower than that in the sham group, whereas the serum TRACP‑5b 
levels in all groups were similar. This result indicates that the 
bone metabolic disorder induced by TG is more dependent on 
suppressing the bone formation compared to on increasing bone 
resorption. Although in the group with TG plus the bisphospho‑
nate the serum TRACP‑5b level appeared lower than those in 
the other TG groups, the individual variability was large and 
this difference was not statistically significant. It is plausible that 
feedback occurred and altered the level of this marker, however, 
this change could not be captured as the present study examined 
only chronic associations. TRACP‑5b is not considered a reflec‑
tion of bone metabolism in this particular model.
As aforementioned, osteoporosis following gastrectomy 
has become a clinical issue. In patients receiving proximal 
gastrectomy or pylorus preserving gastrectomy, which 
preserves gastric acid secretion, reflux of gastric acid 
could be another cause of esophagitis. PPIs are typically 
effective in these patients (37,38). Certain epidemiological 
studies suggested that PPIs induce skeletal metabolism 
disorders. However, due to the effect of PPIs on osteoclasts, 
the administration of PPI may improve TG‑induced bone 
metabolic disorders. The present study used the TG model 
to reproduce the poor calcium absorption that occurs during 
gastric anacidity. As the effect of calcium malabsorption due 
to rabeprazole‑induced gastric acid suppression could be 
excluded, the specific effects of rabeprazole on osteoclasts 
could be examined. Rabeprazole inhibited the TG‑induced 
bone density decrease, suggesting that the administration of 
a PPI is at least not an exacerbating factor in bone metabolic 
disorders.
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